

2019 DIA-NIFDS Workshop

Science Based Drug Development and Approval - Small Molecule and Biologics

21-22 August, 2019 | Chungbuk C&V Centre, Osong KOREA

Advisory Committee



Dr. Dong-hee Lee
Director General of
Institute
MFDS



Dr. Kyung Won Seo
Director General NIFDS
MFDS



Dr. Soojung Sohn
Director General NIFDS
MFDS

Program Committee



Chair
Dr. Hae-Young Ahn
President
Ahn Bio



Co-Chair
Dr. Ho Jung Oh
Director NIFDS
MFDS



Dr. SangAeh Park
Director NIFDS
MFDS



Dr. Hojeong Kim
Director NIFDS
MFDS



Dr. Jee Eun Lee
GC Pharma

For small-molecule drugs, the path to a marketed drug is arduous and because of its complexity, drug discovery and development is widely recognized as one of the most financially risky endeavors and a major challenge for the biomedical industry. The discovery and development process for biologics even more complexed path, and success is far from certain.

In recent times biologics too have attracted much attention primarily because the commercial potential of biologics is very promising and is delivering a better overall economic return than small molecule drugs.

With this backdrop DIA-NIFDS, jointly brings to you a **Workshop on Science Based Drug Development and Approval- Small Molecule and Biologics**.

During the two days this unique workshop would encompass topics covering the spectrum of Small molecules and Biologics and keys must know from early stage development.

Be a part of the series of strategic discussions on current regulatory landscape in NIFDS and FDA and Industry perspectives from experts who have hands on experiences.

A few Key topics:

- Anticancer and Pediatric Drugs Development
- Modeling and Simulation in Drug Development
- Regulation for Cell and Gene Therapy Products
- CMC for Small and Biologics
- Bioanalysis in Drug Development

Registration

Please go to: <http://diaglobal.org/Korea>

or

Please contact us at Korea@DIAGlobal.org, for assistance

8:15-8:45 **Welcome and Registration**

8:50-9:00 **Opening Remarks**

Director General NIFDS
MFDS

9:00-9:20 **Keynote Presentation 1**
Clinical Trials in Korea : Current Status and Future Strategies

Kyung Won Seo
Director General NIFDS
MFDS

9:20-10:10 **Keynote Presentation 2**
Digital Transformation in Healthcare through AI

AI Koh
CEO, Microsoft Korea

10:10-10:30 Coffee Break

Session 1: Strategy and Regulatory Science of Non-Clinical Development

Session Chair
Chang Won Park
NIFDS

10:30-11:15 **Nonclinical Development of Anticancer and Pediatric Drugs: A Regulatory Perspective**

Yangmee Shin*
KWISE

11:15-12:00 **Strategy on Non-Clinical Development of CNS Drugs**

Jung-Shin Park
SK Biopharmaceuticals

12:00-13:00 Lunch

Session 2: Orphan Drug Development and Approval in Regulatory Perspective

Session Chair
Jin-A Jung
Hanmi

13:00-13:45 **Clinical Pharmacology in Drug Development for Rare and Rare Pediatric Diseases**

Insook Kim*

13:45-14:30 **Orphan Drug Designation and a Regulatory Perspective**

Myeong-Ah Chung
NIFDS

14:30-15:15 **Importance Of Bioanalysis in Drug Development**

Chongwoo Yu*

15:15-15:30 Coffee Break

Session 3: Impact of PK-PD Modelling and Simulation on Drug Development and Approval

Session Chair
Dong-Seok Yim
Catholic Univ.

15:30-16:15 **Regulatory Impact of Pharmacometrics**

Jee Eun Lee*
GC Pharma

16:15-17:00 **Application of Modeling & Simulation in Clinical Drug Development: Case Studies**

Holly Kimko
AstraZeneca

17:00-17:45 **PK-PD Model Based Drug Development Experienced in Korea**

Hyeong-Seok Lim
Asan Medical Center

17:45-18:00 **Closing Remarks**

HoJung Kim
Director NIFDS
MFDS

9:00-9:20 **Keynote Presentation 3**
Present and Future Strategies for Biopharmaceuticals in Korea

Soojung Sohn
Director General NIFDS
MFDS

Session 4: Current Trends in Cell and Gene Therapy Products from Regulatory Perspective

Session Chair
Ho-Sang Jeong
NIFDS

9:20-10:05 **Clinical Development of Cellular and Gene Therapy Products**

Lei Xu*
CBER, FDA

10:05-10:50 **Regulation for Cell and Gene Therapy Products in Korea**

Kyoung Suk Choi
NIFDS

10:50-11:05 Coffee Break

Session 5: Biologics - Innovation and Challenges from CMC perspective

Session Chair
Ho Jung Oh
NIFDS

11:05-11:50 **CMC-Related Technical and Regulatory Aspects for Development of Biotherapeutic Products**

Jun Park*
Helixmith

11:50-12:35 **Antibody Drug Manufacturing and Quality Control (Tentative)**

Sangyoon Lee
Celltrion

12:35-13:30 Lunch

Session 6: Non-Clinical Safety Evaluation of Advanced Therapies

Session Chair
Jong Kwon Lee
NIFDS

13:30-14:15 **Preclinical Considerations of Cell and Gene Immunotherapy Drugs**

Kyoung-Sik Moon
KIT

14:15-15:00 **Toxicology of Immuno-oncology**

Woo Chan Son
Univ of Ulsan, Medical School

Session 7: Global Entry for New Drug Development

Session Chair
Younglim Kim
NIFDS

15:00-15:45 **CMC Information Recommended for INDs and NDAs**

Giljong Kang*
C & O Pharma Consultants

15:45-16:30 **Hanmi Footprints and Reshaping for Global Clinical Trials**

Kyounghee Seo
Hanmi

16:30-16:45 Coffee Break

16:45-17:30 **Patient Centric Drug Development and Approval: Factors Affecting Dose and Dosing Regimen**

Hae-Young Ahn*
Ahn Bio

17:30-17:45 **Closing Remarks**

Ho Jung Oh
NIFDS

